My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

Conditions

• Biliary Cancer
• Bladder Cancer
• Neoplasms
• Salivary Cancer
• Solid Tumors

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Trastuzumab — DRUG
  Trastuzumab will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
• Pertuzumab — DRUG
  Pertuzumab will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
• Erlotinib — DRUG
  Erlotinib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
• Vemurafenib — DRUG
  Vemurafenib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
• Cobimetinib — DRUG
  Cobimetinib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
• Vismodegib — DRUG
  Vismodegib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
• Alectinib — DRUG
  Alectinib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
• Atezolizumab — DRUG
  Atezolizumab will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.

Study Details

This multicenter, non-randomized, open-label study will evaluate the efficacy and safety of six treatment regimens in participants with advanced solid tumors for whom therapies that will convey clinical benefit are not available and/or are not suitable options per the treating physician's judgment.

Key Dates

Start date

Apr 14, 2014

Status verified

Jun 2024

Primary completion

May 24, 2023

Completion

May 24, 2023

Study Design

Enrollment

673 participants (actual)

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: Trastuzumab Plus Pertuzumab
  Participants will receive trastuzumab 8 milligrams per kilogram (mg/kg) intravenous (IV) infusion as loading dose, followed by 6 mg/kg IV infusion every 3 weeks; and pertuzumab 840 mg IV infusion as loading dose, followed by 420 mg IV infusion every 3 weeks.
• Experimental: Atezolizumab
  Participants will receive atezolizumab 1200 mg IV infusion every 3 weeks.
• Experimental: Vemurafenib
  Participants will receive vemurafenib 960 mg orally twice daily (BID) in each 28-day cycle.
• Experimental: Vemurafenib Plus Cobimetinib
  Participants will receive vemurafenib 960 mg orally twice daily (BID) in each 28-day cycle; and cobimetinib 60 mg orally once daily for 21 days on and 7 days off in each 28-day cycle.
• Experimental: Vismodegib
  Participants will receive vismodegib 150 mg orally once daily in each 28-day cycle.
• Experimental: Alectinib
  Participants will receive alectinib 600 mg orally BID in each 28-day cycle.
• Experimental: Erlotinib
  Participants will receive erlotinib 150 mg orally once daily in each 28-day cycle.

Primary Outcome Measure

Percentage of Participants in All Tumor-Pathway Cohorts With Overall Response, as Assessed by the Investigator [ Time Frame: From the date of first study treatment until disease progression or death from any cause, whichever occurs first (72.1 months) ]

Locations (60)

Find similar trials in Goodyear, AZ

Related Studies

• Evaluation for NCI Surgery Branch Clinical Research Protocols
  Recruiting · National Cancer Institute (NCI) · Bethesda, Maryland
• Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease
  Recruiting · National Cancer Institute (NCI) · Bethesda, Maryland
• Collection of Tissue Specimens From Patients With Solid Tumors or Blood Disorders and Their HLA-Compatible Family Members
  Recruiting · National Heart, Lung, and Blood Institute (NHLBI) · Bethesda, Maryland
• Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy
  Recruiting · Stanford University · Stanford, California